BÜHLMANN fCAL® ELISA, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US.
- info@buhlmannlabs.ch
- +41 61 487 12 12
Uncategorized
Quantum Blue® Infliximab Citation: F. I. Bantleon, S. Kräuchi, T. B. Schuster, M. Schneider, A. P. Abel Read Citation
Read more
In this video, Dr James Turvill from the York Teaching Hospital introduces and details the York Faecal Calprotectin Care Pathway. He gives a short introduction on the role of calprotectin in stool samples in inflammatory bowel disease (IBD) and its use according to the NICE guidelines. Under his leadership, the local IBD Team developed a Care
Sensitive Screening for anti-neural antibodies is a key step to identify autoimmune peripheral neuropathies. The new Neuroimmunology flyer explains why BÜHLMANN GanglioCombiTM MAG ELISA is the most sensitive screening for anti-Ganglioside and -MAG antibodies in one single step and why anti-MAG antibody ELISA is the gold standard. Click here to get access to the new
Social Links